 Aim 1: To conduct a pilot clinical trial to establish feasibility and to collect first effectiveness data for the use of tACS to renormalize pathological alpha oscillations in the dorsolateral prefrontal cortex dl-pfc of unmedicated patients with MDD by comparing MADRS scores from baseline and one month follow up. 